Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXAS1 | P24557 | 1/20 | 0.31 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.31 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.31 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.31 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.31 |
| ▸ | CAMK2B | Q13554 | 1/20 | 0.31 |
| ▸ | CAMK2G | Q13555 | 1/20 | 0.31 |
| ▸ | CAMK2D | Q13557 | 1/20 | 0.31 |
| ▸ | TAOK1 | Q7L7X3 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4028898 | 0.65 | PGR (0.44) | TBXAS1MAPT | |
| SCHEMBL4026152 | 0.61 | PGR (0.46) | — | |
| SCHEMBL12377075 | 0.59 | HRH1 (0.60) | L3MBTL1MAPTNPSR1 | |
| SCHEMBL24712708 | 0.59 | HRH1 (0.55) | L3MBTL1ALDH1A1TDP1MAPTNPSR1 | |
| SCHEMBL919038 | 0.58 | CYP1A2 (0.58) | CSNK1A1CSNK1DPRKCDPAK1CAMK2B | |
| SCHEMBL73826 | 0.57 | CYP1A2 (0.52) | CSNK1A1CSNK1DPRKCDPAK1CAMK2B | |
| SCHEMBL8523169 | 0.57 | LTB4R (0.55) | CSNK1A1CSNK1DPRKCDPAK1CAMK2B | |
| SCHEMBL9245898 | 0.56 | CHRM2 (0.44) | — | |
| SCHEMBL12072021 | 0.56 | ALOX5 (0.50) | CSNK1A1CSNK1DPRKCDPAK1CAMK2B | |
| SCHEMBL21243277 | 0.56 | CYP1A2 (0.51) | CSNK1A1CSNK1DPRKCDPAK1CAMK2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090275565-A1 | Substituted aralkyl derivatives | CADILA HEALTHCARE LIMITED (IN) | 2009-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275565-A1 | Substituted aralkyl derivatives | UGT1A7, UGT1A10, UGT2B7 | TBXAS1 436/4885CSNK1A1 488/4885CSNK1D 221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.